Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

• Published in: Breast (Edinburgh) Vol. 66; pp. 77 - 84
• Main Authors: Salvador Bofill, Javier, Moreno Anton, Fernando, Rodriguez Sanchez, Cesar Augusto, Galve Calvo, Elena, Hernando Melia, Cristina, Ciruelos Gil, Eva Maria, Vidal, Maria, Jiménez-Rodriguez, Begoña, De la Cruz Merino, Luis, Martínez Jañez, Noelia, Villanueva Vazquez, Rafael, de Toro Salas, Ruben, Anton Torres, Antonio, Alvarez Lopez, Isabel Manuela, Gavila Gregori, Joaquin, Quiroga Garcia, Vanesa, Vicente Rubio, Elena, De la Haba-Rodriguez, Juan, Gonzalez-Santiago, Santiago, Diaz Fernandez, Nieves, Barnadas Molins, Agusti, Cantos Sanchez de Ibargüen, Blanca, Delgado Mingorance, Juan Ignacio, Bellet Ezquerra, Meritxell, de Casa, Sonia, Gimeno, Asuncion, Martin, Miguel
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.12.2022; Elsevier
• Subjects: Advanced breast cancer; Aminopyridines - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Aromatase Inhibitors - therapeutic use; Breast Neoplasms - pathology; CDK4/6 inhibitor; Female; Humans; Letrozole; Middle Aged; Neutropenia - etiology; Original; Postmenopausal; Premenopausal; Protein Kinase Inhibitors - therapeutic use; Receptor, ErbB-2 - metabolism; Ribociclib; Postmenopausal; QTcF; ABC; PR; Advanced breast cancer; FACT-B; Ribociclib; ALT; CNS; HR; PRO; ORR; CDK4/6 inhibitor; SD; TTP; CBR; ECOG; Premenopausal; HRQoL; PFS; SS; AST; RECIST; AE; AESI; CDK4/6; OS; CI; LPLV; CR; ET; SAE; LPFV; NE; FAS; FPFV; HER2

Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hormone receptor-positive (HR+), human epidermal growth factor re...